Figure 1From: Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Change in LDL subclass pattern in the overall population and by baseline triglyceride levels (<150 or ≥150 mg/dL) in high risk patients treated for 6 weeks with ezetimibe added to atorvastatin 40 mg vs atorvastatin 80 mg. P-values are for between-treatment comparison (Atorva 40 + EZ vs Atorva 80)Back to article page